April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Ocular Safety of Intravitreal Propranolol in a Rabbit Model
Author Affiliations & Notes
  • Mozhgan Rezaei Kanavi
    Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran
  • Hamid Ahmadieh
    Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran
  • Ramin Nourinia
    Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran
  • Amirreza Kahrkaboudi
    Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran
  • Adib Tousi
    Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran
  • Bagher Hosseini
    Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran
  • Seyed Iman Taghavi Dinani
    Department of Clinical Sciences, Science and Research Branch, Islamic Azad University, Tehran, Islamic Republic of Iran
  • Seyed Javid Aldavood
    Veterinary Faculty, University of Tehran, Tehran, Islamic Republic of Iran
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 2352. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mozhgan Rezaei Kanavi, Hamid Ahmadieh, Ramin Nourinia, Amirreza Kahrkaboudi, Adib Tousi, Bagher Hosseini, Seyed Iman Taghavi Dinani, Seyed Javid Aldavood; Ocular Safety of Intravitreal Propranolol in a Rabbit Model. Invest. Ophthalmol. Vis. Sci. 2014;55(13):2352.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Propranolol, as a nonselective β-adrenergic receptor blocker, may be a new promising treatment for various ocular vasculopathies. To determine whether propranolol may be used safely as an intraocular drug, the ocular safety of intravitreal propranolol in rabbits was studied by ophthalmoscopy, electrophysiological testing, and histopathologic analysis.

Methods: Twenty eight New Zealand Albino rabbits were categorized into 4 groups (n=7). Each animal was randomized to receive either 15µL BSS alone or propranolol at 15µg, 30µg, and 60µg/15µL in the right eye by intravitreal injection. Ophthalmoscopy and electroretinogram (ERG) recordings were made before and 1 and 4 weeks after injection. Eventually, the rabbits were euthanized and the retinas were examined for histopathologic evaluations and immunohistochemical study for glial fibrillary acidic protein (GFAP).

Results: Fundus examinations were unremarkable in all eyes. ERG evidenced no significant difference between control and propranolol-injected eyes at doses of 15µg and 30µg/15µL. However, mean scotopic b-wave amplitude measured 4 weeks after injection was significantly reduced in eyes receiving 60µg/15µL propranolol (p=0.06). Light microscopy of retina was unremarkable in all eyes. GFAP immune-reactivity of retinal Muller cells supported the ERG results; it was significantly increased in the 60µg/µL-injected eyes but was not different between control and propranolol-injected eyes at doses of 15µg and 30µg/15µL.

Conclusions: Our study did not find evidence of retinal toxicity from intravitreal injection of less than 30µg/15µL propranolol in rabbits.

Keywords: 561 injection • 688 retina  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×